‘Highly contagious’ new STD on the rise as first case reported in US

The first case of a rare, sexually transmitted form of ringworm has been reported in the US, with experts warning it is “highly contagious”.

A new strain of sexually transmitted fungus called Trichophyton mentagrophytes type VII was discovered in a 30-year-old man.

The details of the fungal STDs were just published in the journal JAMA Dermatology by doctors at NYU Langone Health in New York — and come as clinicians around the world increasingly report problems treating yeast infections.

“Healthcare providers should be aware that Trichophyton mentagrophytes type VII [TMVII] is the latest in a series of severe skin infections that have now reached the United States,” said Dr. Avrom S. Caplan, assistant professor in the department of dermatology at NYU Grossman School of Medicine.

dr. Caplan co-authored a case study published Wednesday of an unidentified New Yorker who contracted TMVII.

After visiting England, Greece and California, a rash appeared on the penis, buttocks and limbs.

He reported having intercourse with several men during his travels, none of whom revealed similar skin problems, NBC reports.

Cases of TMVII are increasing in Europe, especially in men who have sex with men. There are currently no known cases in Australia.

“Since patients are often reluctant to discuss genital problems, clinicians should ask directly about rashes around the groin and buttocks, especially those who are sexually active, have recently traveled abroad, and report itchy areas elsewhere on the body,” lead study author . dr. John G. Zampella advised.

dr. Zampella noted that infections caused by TMVII seem to respond to standard antifungal therapies, such as the drug terbinafine, but can take months to clear up. They can also be mistaken for lesions caused by eczema, which can delay healing.

A different itchy and contagious skin infection that causes TMVII-like rashes has proved more challenging for dermatologists, New York Post reports.

Trichophyton indotineae — which is widespread in India and was first confirmed in the U.S. last year — often resists treatment with terbinafine, according to researchers at NYU’s Grossman School of Medicine.

They analyzed data from 11 men and women treated for Trichophyton indotineae in New York City hospitals between May 2022 and May 2023.

Seven patients received standard doses of terbinafine. Their rashes did not go away, possibly due to genetic mutations in the fungus.

The antifungal pill itraconazole gave better results, but Dr. Caplan warned that the drug can interact with other medications and cause nausea and diarrhea, among other side effects.

Dr. Caplan said that while dermatologists should be aware of TMVII and Trichophyton indotineae, rates in the U.S. remain low for now. His team hopes to expand their research to these two types of fungi in the next few months.

“These [initial] The findings offer new insight into how some fungal skin infections spreading from South Asia can evade our mainstream therapies,” said Dr. Caplan. “In addition to learning to recognize their misleading signs, doctors will need to ensure that their treatment meets each patient’s quality of life needs.”

— with The New York Post

Leave a Comment